BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 09, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 11/6 cls
Actelion Ltd. (SIX:ATLN) UBS Martin Wales Upgrade Neutral (from sell) 3% CHF58.10
Wales upgraded after Actelion guided for stronger Tracleer bosentan pricing in the near term despite weak 3Q09 sales for the dual endothelin A and B receptor antagonist in pulmonary arterial hypertension (PAH).
Array BioPharma Inc. (NASDAQ:ARRY) UBS Jeff Elliott Upgrade Buy (from neutral) 12% $2.00
Elliot cited the potential for a partnership in 2010. He thinks Array's pipeline is undervalued based on comps for recent oncology partnerships. The company has several compounds in early clinical development for cancer, including MEK inhibitor ARRY-162.
Biogen Idec Inc. (NASDAQ:BIIB) Jefferies Eun Yang Upgrade Buy (from hold) 9%...

Read the full 745 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >